Merieux Equity Partners acquired a significant minority stake in Health in Code, joining forces with Alantra and the management team. The transaction aims to provide the capital and industrial expertise needed to double the company's size, with a goal of reaching EUR100 million in revenue within five years. The strategic rationale focuses on aggressive international expansion into key European markets, enhancing the bioinformatics software suite, and pursuing selective M&A to consolidate the fragmented European genetics market.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.